[go: up one dir, main page]

LT2676967T - Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu - Google Patents

Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu

Info

Publication number
LT2676967T
LT2676967T LTEP13175987.0T LT13175987T LT2676967T LT 2676967 T LT2676967 T LT 2676967T LT 13175987 T LT13175987 T LT 13175987T LT 2676967 T LT2676967 T LT 2676967T
Authority
LT
Lithuania
Prior art keywords
natalizumab
methods
autoimmune diseases
treating inflammatory
inflammatory
Prior art date
Application number
LTEP13175987.0T
Other languages
English (en)
Inventor
Ivan Lieberburg
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38459615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2676967(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of LT2676967T publication Critical patent/LT2676967T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
LTEP13175987.0T 2006-02-28 2007-02-28 Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu LT2676967T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77693106P 2006-02-28 2006-02-28

Publications (1)

Publication Number Publication Date
LT2676967T true LT2676967T (lt) 2019-09-10

Family

ID=38459615

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13175987.0T LT2676967T (lt) 2006-02-28 2007-02-28 Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu

Country Status (13)

Country Link
US (6) US20070207141A1 (lt)
EP (4) EP4276469A3 (lt)
JP (2) JP2009528359A (lt)
CA (2) CA2641513C (lt)
CY (1) CY1122031T1 (lt)
DK (1) DK2676967T3 (lt)
ES (1) ES2752137T3 (lt)
HU (1) HUE047230T2 (lt)
LT (1) LT2676967T (lt)
PL (1) PL2676967T3 (lt)
PT (1) PT2676967T (lt)
SI (1) SI2676967T1 (lt)
WO (1) WO2007100770A2 (lt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
DK2645106T4 (da) 2005-04-04 2024-12-02 Biogen Ma Inc Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
RS20080391A (sr) * 2006-03-03 2009-07-15 Elan Pharmaceuticals Inc., Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
CN102770151B (zh) 2009-08-03 2018-07-31 因卡伯实验室有限责任公司 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法
ES2731052T3 (es) 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
JP2013507618A (ja) 2009-10-11 2013-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｖｌａ‐４関連アッセイ
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
RS63744B1 (sr) 2010-01-11 2022-12-30 Biogen Ma Inc Test za antitela protiv jc virusa
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
KR20150135552A (ko) 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
WO2011109531A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) * 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
ES2729945T3 (es) * 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AU2012325013A1 (en) 2011-10-17 2014-03-27 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of PML and related apparatus
EP2773779B1 (en) 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9161935B2 (en) * 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
CN103845726A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 克拉屈滨和乙酸格拉默的组合用于治疗多发性硬化的用途
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3511422B1 (en) 2013-11-12 2022-12-28 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
IL251210B2 (en) * 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
CA3108807A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7
EP4288073A4 (en) * 2021-02-05 2025-03-26 University of Utah Research Foundation Compositions and methods for treating with car cells

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
WO1992012428A1 (en) 1991-01-11 1992-07-23 Quidel Corporation A one-step lateral flow nonbibulous assay
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
EP1232392B2 (de) 1999-10-12 2014-04-02 Oxoid (Ely) Limited Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US6388084B1 (en) * 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
AU4465001A (en) 2000-03-30 2001-10-15 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) * 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004511807A (ja) 2000-10-17 2004-04-15 ベッスト−テスト　アンパーツゼルスカブ 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
AU2002331408B2 (en) 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
US6605602B1 (en) * 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
US7754433B2 (en) 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2004001539A2 (en) 2002-06-21 2003-12-31 Mckesson Information Solutions Llc Closed loop medication use system and method
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
AR050425A1 (es) * 2004-07-08 2006-10-25 Elan Pharm Inc Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
DK2645106T4 (da) 2005-04-04 2024-12-02 Biogen Ma Inc Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
CA2624450C (en) * 2005-09-29 2014-02-04 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
MY151045A (en) 2006-02-27 2014-03-31 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
RS20080391A (sr) 2006-03-03 2009-07-15 Elan Pharmaceuticals Inc., Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
ES2842425T3 (es) 2009-02-05 2021-07-14 Biogen Ma Inc Métodos para la detección del poliomavirus JC
US9354233B2 (en) 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
RS63744B1 (sr) 2010-01-11 2022-12-30 Biogen Ma Inc Test za antitela protiv jc virusa
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法

Also Published As

Publication number Publication date
US20070207141A1 (en) 2007-09-06
CA2641513A1 (en) 2007-09-07
ES2752137T3 (es) 2020-04-03
WO2007100770A2 (en) 2007-09-07
PL2676967T3 (pl) 2019-12-31
SI2676967T1 (sl) 2020-01-31
EP1988921A4 (en) 2010-02-10
US20190315871A1 (en) 2019-10-17
JP2015007103A (ja) 2015-01-15
EP2676967A3 (en) 2014-03-05
EP2676967B1 (en) 2019-08-14
EP4276469A2 (en) 2023-11-15
HUE047230T2 (hu) 2020-04-28
US9493567B2 (en) 2016-11-15
US20100196318A1 (en) 2010-08-05
US10233245B2 (en) 2019-03-19
US20240400694A1 (en) 2024-12-05
CA2641513C (en) 2021-09-21
US20170022276A1 (en) 2017-01-26
EP4276469A3 (en) 2024-01-17
US20170247457A1 (en) 2017-08-31
PT2676967T (pt) 2019-09-27
EP2676967A2 (en) 2013-12-25
DK2676967T3 (da) 2019-09-16
EP3620469A1 (en) 2020-03-11
CA3127202A1 (en) 2007-09-07
US11292845B2 (en) 2022-04-05
EP1988921A2 (en) 2008-11-12
JP2009528359A (ja) 2009-08-06
WO2007100770A3 (en) 2008-12-11
CY1122031T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
HUE047230T2 (hu) Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
ZA200807346B (en) Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2007392A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
HUS2100015I1 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
IL211034A0 (en) Treatment of autoimmune and inflammatory disease
EP2084527A4 (en) METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
PL2056807T3 (pl) Leczenie chorób zakaźnych
EP2076526A4 (en) NEW SIRNA AND METHOD FOR ITS APPLICATION
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
PT3279663T (pt) Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
IL215392A0 (en) Methods of predicting clinical course and treating multiple sclerosis
IL206125A0 (en) Azaindolizines and methods of use
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
EP2021016A4 (en) CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
PL2012814T3 (pl) Sposoby leczenia chorób autoimmunologicznych
EP2076197A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
PL2049556T3 (pl) Nowe makrolidy użyteczne przeciw chorobom zapalnym i alergicznym
SI2012814T1 (sl) Postopki za zdravljenje avtoimunskih bolezni
HK1152532A (en) Treatment of autoimmune and inflammatory disease
IL198070A0 (en) NOVEL siRNAS AND METHODS OF USE THEREOF
HK1150453A (en) Methods of diagnosing and treating parp-mediated diseases
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same